The NK cancer drug provider has filed to go public in an offering which would enable GC and its GC Labcell subsidiary to exit.
Artiva Biotherapeutics, a US-based immunotherapy developer backed by pharmaceutical group GC, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2019, Artiva is working on cell-based cancer therapies. Its lead drug candidate, AB-101, helps the body produce natural killer (NK) cells that destroy cancer and tumour cells. The proceeds…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.